Payment overview · 2025
General Payments
$799.14
33 reported records · 10 companies
Healthcare provider profile · identity verified
Marina Volpin, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1497771018
Verified facts
What the public records show
CMS Open Payments records show Marina Volpin, M.D. received $799.14 in general payments during 2025 across 33 reported records.
ABBVIE INC. accounted for 24.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Linzess, Prolia, Trelegy Ellipta, Ubrelvy, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 188 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 292 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Ubrelvy by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 272 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 351 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $194.84 | 24.4% | 9 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $163.28 | 20.4% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $122.91 | 15.4% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $90.50 | 11.3% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $68.02 | 8.5% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $58.09 | 7.3% | 3 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $35.50 | 4.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $27.27 | 3.4% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.22 | 2.7% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.51 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $799.14 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $163.28 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $122.91 | 5 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $102.93 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $91.91 | 5 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $68.02 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $58.09 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $52.53 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $45.96 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $44.54 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $44.54 | 2 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $35.50 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $27.27 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $21.75 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $21.22 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $17.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 188 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 292 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 20 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 169 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 272 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
188 | 48 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
292 | 43 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
161 | 25 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
272 | 47 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
20 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
351 | 61 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
169 | 36 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 911 | 174 |
| Atorvastatin Calcium | Atorvastatin Calcium | 864 | 168 |
| Metoprolol Succinate | Metoprolol Succinate | 683 | 118 |
| Diclofenac Sodium | Diclofenac Sodium | 625 | 112 |
| Omeprazole | Omeprazole | 614 | 116 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 540 | 105 |
| Losartan Potassium | Losartan Potassium | 527 | 105 |
| Eliquis | Apixaban | 351 | 61 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 328 | 69 |
| Zolpidem Tartrate | Zolpidem Tartrate | 324 | 65 |
| Gabapentin | Gabapentin | 318 | 59 |
| Escitalopram Oxalate | Escitalopram Oxalate | 302 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 297 | 56 |
| Linzess | Linaclotide | 292 | 43 |
| Vascepa | Icosapent Ethyl | 281 | 46 |
| Furosemide | Furosemide | 272 | 53 |
| Zenpep | Lipase/Protease/Amylase | 272 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 265 | 64 |
| Carvedilol | Carvedilol | 263 | 40 |
| Metformin Hcl | Metformin Hcl | 261 | 46 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 259 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 250 | 55 |
| Ezetimibe | Ezetimibe | 247 | 47 |
| Famotidine | Famotidine | 231 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 230 | 46 |
| Dexlansoprazole Dr | Dexlansoprazole | 226 | 45 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 209 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 207 | 61 |
| Creon | Lipase/Protease/Amylase | 188 | 48 |
| Levothyroxine Sodium | Levothyroxine Sodium | 184 | 39 |
| Ammonium Lactate | Ammonium Lactate | 182 | 49 |
| Ibuprofen | Ibuprofen | 182 | 43 |
| Meloxicam | Meloxicam | 174 | 34 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 169 | 36 |
| Synthroid | Levothyroxine Sodium | 161 | 25 |
| Ranolazine Er | Ranolazine | 154 | 23 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 149 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 149 | 31 |
| Simvastatin | Simvastatin | 145 | 23 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 132 | 22 |
| Ventolin Hfa | Albuterol Sulfate | 130 | 26 |
| Myrbetriq | Mirabegron | 127 | 17 |
| Metformin Hcl Er | Metformin Hcl | 125 | 28 |
| Celecoxib | Celecoxib | 124 | 21 |
| Enalapril Maleate | Enalapril Maleate | 121 | 24 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 120 | 24 |
| Dicyclomine Hcl | Dicyclomine Hcl | 115 | 23 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 115 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 113 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 111 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 110 | 21 |
| Meclizine Hcl | Meclizine Hcl | 110 | 28 |
| Icosapent Ethyl | Icosapent Ethyl | 106 | 24 |
| Allopurinol | Allopurinol | 99 | 17 |
| Januvia | Sitagliptin Phosphate | 97 | 19 |
| Single Use Swab | Alcohol Antiseptic Pads | 96 | 21 |
| Ketoconazole | Ketoconazole | 93 | 14 |
| Finasteride | Finasteride | 90 | 16 |
| Potassium Chloride | Potassium Chloride | 90 | 14 |
| Atenolol | Atenolol | 89 | 19 |
| Lisinopril | Lisinopril | 86 | 22 |
| Montelukast Sodium | Montelukast Sodium | 85 | 14 |
| Dexilant | Dexlansoprazole | 84 | 12 |
| Jardiance | Empagliflozin | 84 | 15 |
| Trulicity | Dulaglutide | 83 | 12 |
| Nitroglycerin | Nitroglycerin | 82 | 37 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 81 | 26 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 79 | 13 |
| Valacyclovir | Valacyclovir Hcl | 77 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 75 | 20 |
| Memantine Hcl Er | Memantine Hcl | 73 | 13 |
| Memantine Hcl | Memantine Hcl | 72 | 12 |
| Alendronate Sodium | Alendronate Sodium | 71 | 12 |
| Lidocaine | Lidocaine | 71 | 13 |
| Pregabalin | Pregabalin | 70 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 69 | 13 |
| Xarelto | Rivaroxaban | 69 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 68 | 11 |
| Donepezil Hcl | Donepezil Hcl | 64 | 13 |
| Entresto | Sacubitril/Valsartan | 59 | 11 |
| Nifedipine Er | Nifedipine | 59 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 58 | 11 |
| Procto-Med Hc | Hydrocortisone | 58 | 12 |
| Colchicine | Colchicine | 54 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 53 | suppressed |
| Ramipril | Ramipril | 52 | suppressed |
| Azithromycin | Azithromycin | 51 | 43 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 51 | suppressed |
| Proctozone-Hc | Hydrocortisone | 51 | 15 |
| Tradjenta | Linagliptin | 51 | suppressed |
| Glimepiride | Glimepiride | 49 | suppressed |
| Glipizide Er | Glipizide | 49 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 49 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 48 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 47 | 13 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 47 | 14 |
| Farxiga | Dapagliflozin Propanediol | 47 | suppressed |
| Loperamide | Loperamide Hcl | 46 | 14 |
| Buspirone Hcl | Buspirone Hcl | 45 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 44 | suppressed |
| Mupirocin | Mupirocin | 43 | 16 |
| Clobetasol Propionate | Clobetasol Propionate | 42 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 42 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 42 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 42 | 13 |
| Hydrocortisone | Hydrocortisone | 41 | 17 |
| Naproxen | Naproxen | 41 | 13 |
| Trazodone Hcl | Trazodone Hcl | 41 | suppressed |
| Valsartan | Valsartan | 41 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 40 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 40 | suppressed |
| Torsemide | Torsemide | 39 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 38 | suppressed |
| Spironolactone | Spironolactone | 38 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 37 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 37 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 36 | suppressed |
| Cyclosporine | Cyclosporine | 35 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 34 | 21 |
| Brilinta | Ticagrelor | 34 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 34 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 34 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | suppressed |
| Methimazole | Methimazole | 32 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 31 | suppressed |
| Ozempic | Semaglutide | 31 | 11 |
| Raloxifene Hcl | Raloxifene Hcl | 31 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 30 | suppressed |
| Nystatin | Nystatin | 30 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 30 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 28 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 27 | suppressed |
| Clonidine | Clonidine | 27 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 27 | 11 |
| Amoxicillin | Amoxicillin | 26 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Clotrimazole | Clotrimazole | 25 | suppressed |
| Eszopiclone | Eszopiclone | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Telmisartan | Telmisartan | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Restasis | Cyclosporine | 23 | suppressed |
| Cilostazol | Cilostazol | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 22 | suppressed |
| Gemtesa | Vibegron | 22 | suppressed |
| Repaglinide | Repaglinide | 22 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 22 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | 14 |
| Bumetanide | Bumetanide | 20 | suppressed |
| Ciclopirox | Ciclopirox | 20 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 20 | suppressed |
| Ibu | Ibuprofen | 20 | suppressed |
| Lactulose | Lactulose | 20 | suppressed |
| Prolia | Denosumab | 20 | 11 |
| Methylprednisolone | Methylprednisolone | 19 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 19 | suppressed |
| Nexium | Esomeprazole Magnesium | 19 | suppressed |
| Ubrelvy | Ubrogepant | 19 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 17 |
| Dutasteride | Dutasteride | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 17 | suppressed |
| Edarbi | Azilsartan Medoxomil | 17 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 17 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 16 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 16 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 16 | suppressed |
| Mesalamine Er | Mesalamine | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Prednisone | Prednisone | 16 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Mesalamine | Mesalamine | 14 | suppressed |
| Nyamyc | Nystatin | 14 | suppressed |
| Rivastigmine | Rivastigmine | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 13 | suppressed |
| Eplerenone | Eplerenone | 13 | suppressed |
| Indapamide | Indapamide | 13 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 13 | suppressed |
| Pyridostigmine Bromide Er | Pyridostigmine Bromide | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Xopenex Hfa | Levalbuterol Tartrate | 13 | suppressed |
| Zerviate | Cetirizine Hcl | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 11 | suppressed |
| Benicar Hct | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Carafate | Sucralfate | 11 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Sure Comfort Alcohol | Alcohol Antiseptic Pads | 11 | suppressed |
| True Comfort Pro Alcohol Pads | Alcohol Antiseptic Pads | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $799.14 · 33 records | ABBVIE INC. | AMVUTTRA, CAMZYOS, CREON, EVENITY, FARXIGA, IBSRELA, LINZESS, OTEZLA, PROLIA, QULIPTA, REPATHA, Symbravo, TRELEGY ELLIPTA, UBRELVY, XIFAXAN, ZENPEP | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error